Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.

Saved in:
Bibliographic Details
Title: Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Authors: Desai AV; Department of Pediatrics, University of Chicago, Chicago, Illinois., Applebaum MA; Department of Pediatrics, University of Chicago, Chicago, Illinois., Karrison TG; Department of Public Health Sciences, University of Chicago, Chicago, Illinois., Oppong A; Pritzker School of Medicine, University of Chicago, Chicago, Illinois., Yuan C; Department of Radiology, University of Chicago, Chicago, Illinois., Berg KR; Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania., MacQuarrie K; Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University, Chicago, Illinois., Sokol E; Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University, Chicago, Illinois., Hall AG; Seattle Children's Hospital and University of Washington, Seattle, Washington., Pinto N; Seattle Children's Hospital and University of Washington, Seattle, Washington., Wolfe I; C. S. Mott Children's Hospital and University of Michigan, Ann Arbor, Michigan., Mody R; C. S. Mott Children's Hospital and University of Michigan, Ann Arbor, Michigan., Shusterman S; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts., Smith V; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas., Foster JH; Texas Children's Hospital and Baylor College of Medicine, Houston, Texas., Nassin M; Department of Pediatrics, University of Chicago, Chicago, Illinois., LaBelle JL; Department of Pediatrics, University of Chicago, Chicago, Illinois., Bagatell R; Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania., Cohn SL; Department of Pediatrics, University of Chicago, Chicago, Illinois.
Source: Cancer [Cancer] 2022 Aug 01; Vol. 128 (15), pp. 2967-2977. Date of Electronic Publication: 2022 Jun 06.
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1097-0142
DOI:10.1002/cncr.34263